Evidence map›Paper›PMID 39765731›Full record

ArticleBiology2024

Effectiveness and Mechanism of Resibufogenin on Human Renal Cancer Cell Caki-1.

Yuqi Wu, Yue Yang, Run Huang, Tao Li, Chunlei Wan, Lei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuqi WuSchool of Life Science and Technology, Mudanjiang Normal University, Mudanjiang 157011, China.ORCID 0009-0003-8068-7059
Yue YangSchool of Life Science and Technology, Mudanjiang Normal University, Mudanjiang 157011, China.ORCID 0009-0009-6740-6818
Run HuangSchool of Life Science and Technology, Mudanjiang Normal University, Mudanjiang 157011, China.ORCID 0009-0008-9221-0369
Tao LiSchool of Life Science and Technology, Mudanjiang Normal University, Mudanjiang 157011, China.ORCID 0000-0003-0338-7688
Chunlei WanSchool of Life Science and Technology, Mudanjiang Normal University, Mudanjiang 157011, China.ORCID 0009-0000-0669-0530
Lei ZhangSchool of Life Science and Technology, Mudanjiang Normal University, Mudanjiang 157011, China.ORCID 0000-0003-3973-6886

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we investigated the effect and mechanism of Resibufogenin on renal cell carcinoma based on network pharmacology, molecular docking, and in vitro experiments. The results showed that there were 35 cross-targets between Resibufogenin and renal cell carcinoma. GO and KEGG pathway analyses indicated that Resibufogenin inhibited renal cancer cells through the vascular smooth muscle contraction signalling pathway and EGFR tyrosine kinase inhibitor resistance signaling pathway, and MAPK1, PRKCB, and Resibufogenin had strong associative activities. After different concentrations of Resibufogenin were applied to human renal cancer cells, it was found that the IC50 value was 408.2 nM, 10 nM resibufogenin could significantly inhibit cell migration (

Indexed as

network pharmacologyrenal cell carcinomaResibufogenin

Identifiers

PMID39765731
PMCPMC11673963

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.